Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;10(1):49-52.
doi: 10.2174/157015912799362788.

Sibutramine effects on central mechanisms regulating energy homeostasis

Affiliations

Sibutramine effects on central mechanisms regulating energy homeostasis

João R Araújo et al. Curr Neuropharmacol. 2012 Mar.

Abstract

During the last 50 years the global pandemic of obesity and associated life-threatening co-morbidities strongly promoted the development of anti-obesity pharmacotherapy. Sibutramine is an anti-obesity drug that in conjunction with lifestyle modifications reduces food intake and body weight. This may result from several effects: inhibition of presynaptic reuptake of monoaminergic neurotransmitters in the central nervous system, thereby suppressing appetite, induction of an increase in anorexigenic and a decrease in orexigenic neuropeptide secretion, induction of an increase in energy expenditure, and induction of peripheral sympathomimetic effects. The effects of sibutramine on anabolic and catabolic signals that regulate energy homeostasis in the hypothalamus are not completely understood. So, the aim of this review is to summarize the central mechanisms of action of sibutramine, responsible for its weight and food intake reducing potential. Despite being a useful drug in obesity treatment, awareness about the loss of long-term effectiveness and detrimental side effects of sibutramine has recently emerged. As a consequence, new drugs that produce safer and more persistent weight loss are currently undergoing clinical trials.

Keywords: Appetite; hypothalamus; obesity; sibutramine; weight loss..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Neuroanatomical model summarizing the different pathways that control energy homeostasis. During meals, episodic and tonic signals, such as the satiety signals cholecystokinin (CCK) and the adiposity signals leptin and insulin, are conveyed through the vagus nerve to the arcuate nucleus (ARC) and nucleus of the solitary tract (NTS). These signals interact with neurons that synthesize anorexigenic and orexigenic neuropeptides, like proopiomelanocorticotropin (POMC)/cocaine amphetamine regulating transcript (CART) or neuropeptide Y (NPY)/agouti related peptide (AgRP), respectively, which in turn project to other hypothalamic areas including the paraventricular nuclei (PVN) and the lateral hypothalamic area (LHA). Figure reproduced, with permission, from Reference [5]. Abbreviations: GI, gastrointestinal; PFA, perifornical area; SNS, sympathetic nervous system.

References

    1. McNeely W, Goa K L. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56(6):1093–1124. - PubMed
    1. Tziomalos K, Krassas G E, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc. Health Risk Manag. 2009;5(1):441–452. - PMC - PubMed
    1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes. Res. 1998;6(Suppl 2):51S–209S. - PubMed
    1. Padwal R S, Majumdar S R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71–77. - PubMed
    1. Schwartz M W, Woods S C, Porte D, Jr, Seeley R J, Baskin D G. Central nervous system control of food intake. Nature. 2000;404(6778):661–671. - PubMed